Compare Citius Pharmaceuticals Inc (CTXR) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Norwegian Cruise Line Holdings Ltd — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Norwegian Cruise Line Holdings Ltd trades at $20.09 (market cap $8.93B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 610× Citius Pharmaceuticals Inc's market cap, and Norwegian Cruise Line Holdings Ltd is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | NCLH | |
|---|---|---|
Market Cap | $14.64M | $8.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $26.94 |
52-Week Low | $0.53 | $14.79 |
Enterprise Value | $10.86M | $23.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Norwegian Cruise Line Holdings (NCLH) trades at $19.63, up 0.1% on the day, with a neutral technical signal and strong analyst consensus. Recent earnings beats and a 55.55% buy rating from analysts support optimism, though the stock faces headwinds from high debt levels and volatile cash flows. Revenue growth has improved from $4.8B in 2022 to $9.83B in 2025, but net margins remain modest at 4.3%.
The outlook is cautiously positive, with a consensus price target of $21.71 offering ~11% upside. Key opportunities include falling energy costs and robust booking trends, while risks involve elevated leverage and macroeconomic sensitivity. Investors should weigh solid fundamentals against balance sheet constraints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
